Rosuvastatin and Upadacitinib interaction
Rosuvastatin and Upadacitinib: both prescribing labels describe an interaction that usually calls for monitoring, a dose change, or spacing the doses.
Usually manageable with monitoring or a dose change. Tell your pharmacist you take both.
What the FDA labels say
From the Upadacitinib (Rinvoq) label · effective 2026-06-30
Elevations in LDL cholesterol decreased to pre-treatment levels in response to statin therapy.
From the Rosuvastatin (Crestor) label · effective 2026-04-29
IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents.
Treatment with immunosuppressive agents may be required.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.